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TP53 CODON 72 SINGLE NUCLEOTIDE POLYMORPHISM 
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Defects in the tumor suppressor gene TP53 are known to be important in chronic lymphocytic leukemia (CLL) and TP53 inac-
tivation is associated with a particularly aggressive form of the disease. The single nucleotide polymorphism in the TP53 gene 
at codon 72 (rs1042522), results in amino acid substitution influencing apoptotic potential of TP53 protein. The aim of the study 
was to evaluate the association of the TP53 codon 72 polymorphism and incidence of TP53 mutations in CLL patients. Methods: 
261 CLL samples were analyzed by polymerase chain reaction and direct sequencing for TP53 mutations and single nucleotide 
polymorphism. Results: The 72Pro/Pro genotype was associated with an increased incidence of TP53 mutations in previously treated 
patients (OR = 2.503; 95% CI 1.142–5.487; р = 0.001). Conclusion: This study revealed that the TP53 codon 72 polymorphism 
may be used as a risk factor for incidence of TP53 mutations in CLL.
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Chronic lymphocytic leukemia (CLL) is characte-
rized by a highly variable clinical course, ranging from 
indolent cases to cases with aggressive and rapidly 
progressing disease [1]. Several prognostic mar kers 
have been identified, including different genomic 
aberrations. Defects in the tumor suppressor gene 
TP53 was found to be associated with particularly 
poor prognosis. The TP53 protein plays a crucial role 
in cellular response to DNA damage by induction 
of apoptosis, cell cycle arrest and DNA repair, thus 
maintaining genomic integrity and mediating the ac-
tion of DNA damaging chemotherapy, as well [2]. 
 Inactivation of TP53 due to deletion of TP53 gene locus 
(17p13), which in the majority of cases (over 80%) 
is accompanied by mutation in the remaining TP53 al-
lele, or due to TP53 mutation alone have been associ-
ated with short survival and chemotherapy resistance 
in a number of studies [3–7]. CLL patients with mutated 
TP53 are considered a high-risk prognostic group, who 
should be offered alternative therapy strategies, acting 
independently of TP53 pathway [8, 9].
The TP53 gene aberrations are relatively infrequent 
at stage of CLL diagnosis or at time of initial therapy, 
ranging from 10% to 15% of cases. However, the inci-
dence rises up to 40–50% in group of patients previously 
treated with chemotherapy and undergo refractory CLL 
[10, 11]. Some known markers of unfavorable CLL prog-
nosis are reported as risk factors for TP53 aberrations — 
an increased expression of CD38, ZAP-70, and unmu-
tated status of immunoglobulin heavy chain variable 
region (IGHV) genes [12, 13]. Recently some preliminary 
data were presented indicating the association between 
TP53 mutations and single nucleotide polymorphism 
(SNP) within the TP53 gene at codon 72 (rs1042522). 
This polymorphism encodes either arginine (72Arg, 
genotype CGC) or proline (72Pro, genotype CCC) and 
significantly affects TP53 function. The 72Arg vari-
ant is more effective at inducing apoptosis than the 
72Pro, while the 72Pro/Pro genotype was associated 
with an increased expression of cell cycle arrest genes 
[14]. Grossmann et al. and Dong et al. have found 
an increased incidence of TP53 mutations and dele-
tions in CLL patients with the 72Pro/Pro genotype [15, 
16]. The same association was found in patients with 
non-melanoma skin cancer [17]. On the contrary, lung 
cancer patients who were the 72Pro allele carriers had 
significantly lower frequency of TP53 mutations in com-
parison with 72Arg homozygotes [18].
To further substantiate the role of the TP53 codon 
72 polymorphism as a risk factor for TP53 mutations, 
we have analyzed the TP53 mutational status in CLL 
patients, carriers of different genotypes in relation 
to clinical characteristics and some molecular pecu-
liarities of B-cell receptor of leukemic cells.
MATERIALS AND METHODS
The TP53 codon 72 SNP was analyzed in 261 con-
secutive patients with CLL, 198 males (75.5%) and 
63 females (24.5%), median age of 58 years at CLL 
diagnosis (range 29–86 years), referred to the State 
Institution “National Research Centre for Radiation 
Medicine, National Academy of Medical Sciences 
of Ukraine”, Kyiv, Ukraine. All patients were inhabitants 
of the central part of Ukraine. The study was approved 
by the local Ethics Review Committee, and all patients 
signed an informed consent form prior to participation 
in the study. CLL was diagnosed on the basis of clini-
cal history, blood lymphocytosis lymphocyte mor-
phology, and immunophenotypic criteria. The stage 
of the disease was assessed by Binet [19] and Rai 
classification [20]. The treatment was initiated in ac-
cordance with the National Cancer Institute of USA 
(NCI) criteria [21].
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Genomic DNA was extracted from peripheral blood 
mononuclear cells with the QIAamp Blood Mini Kit (Qia-
gen, Crawley, United Kingdom) according to the manu-
facturer’s protocol. At the time of blood samples col-
lection, 172 (65.9%) patients were either at diagnosis 
or before the initial treatment (median of observation 
was 41 months) and remained 89 of 261 (34.1%) patients 
received therapy (median of observation was 75 months). 
The IGHV gene mutational status was assessed by PCR 
amplification followed by direct sequencing according 
to the BIOMED-2 consortium rules [22], as described 
above [23]. Sequences were analyzed using the IgBlast 
and IMGT databases. The IGHV gene was considered un-
mutated when the identity to the corresponding germline 
gene was more than or equal 98%.
TP53 gene mutation analysis was performed for 
exons 3–10 in the majority of cases (245/261), and for 
exons 5–9 (region, where the vast majority of muta-
tions are located), in 16 cases. Study was done by PCR 
amplification followed by direct sequencing with Big-
Dye Term v3.1 cycle sequencing chemistry (Applied 
Biosystems Foster City, CA). Data were compared 
with reference TP53 gene sequence NC_000017.10, 
and mutations were validated using the International 
Agency for Research on Cancer (IARC) TP53 Mu-
tation Database (www.p53.iarc.fr) [24]. For exons 
3–10 analysis five fragments were amplified, spanning 
3–4, 5–6, 7, 8–9 and 10 exons. Primers were kindly 
designed by Dr. V. Saenko (Atomic Bomb Disease 
Institute, Nagasaki University), all primer sequences 
are available on demand. PCR was performed using 
10 ng of DNA in a 25 μL reaction mixture containing 
0.3 μM of each primer, 1.5 mM MgCl2, 0,8 mM dNTPs, 
and 0.125 U of AmpliTaqGold DNA polymerase (Applied 
Biosystems, Foster City, CA, USA), or 0.25 U of KOD-
Plus-Neo DNA polymerase (Toyobo, Osaka, Japan). 
PCR conditions were optimized for each primer pair. 
In cases, where exons 5–9 only were analyzed, PCR 
primers and reaction conditions according to IARC 
protocol, 2010 were used (www.p53.iarc.fr). Primers 
and length of amplified fragments are listed in Table 1. 
PCR was performed with 50 ng of DNA in a total volume 
of 25 μL reaction mixture consisting of 0.4 μM of each 
primer, 1.5 mM MgCl2, 0.8 mM dNTPs, 0.125 U of Am-
pliTaqGold DNA polymerase (Applied Biosystems, 
Foster City, CA, USA). PCR conditions were as follows: 
initial denaturation step of 3 min at 95 °C, 20 cycles 
of 30 s at 95 °C, 45 s at 63 °C (reducing at 0.5 °C every 
3 cycles) and 45 s at 72 °C, with following 30 cycles 
of 30 s at 95 °C, 45 s at 60 °C and 45 s at 72 °C.
Table 1. Primer sequences used for the TP53 gene mutation analysis 
( exons 5–9)
Region 
amplified Forward primer (5´  3´) Reverse primer (5´  3´)
Ampli-
con 
size
Exons 5–6 TGTTCACTTGTGCCCTGACT TTAACCCCTCCTCCCAGAGA 467 bp
Exon 7 AGGCGCACTGGCCTCATCTT TGTGCAGGGTGGCAAGTGGC 177 bp
Exons 8–9 TTGGGAGTAGATGGAGCCT AGTGTTAGACTGGAAACTTT 445 bp
The TP53 codon 72 SNP was assessed by analysis 
of exon 4 fragment sequences (Fig. 1), or by PCR-re-
striction fragment length polymorphism (RFLP) method 
according to Hirata et al. [25] in that cases, where exons 
5–9 only were analyzed. For genotyping by RFLP me-
thod PCR was carried out using 50 ng of DNA in a total 
volume of 20 μL consisting of 0.5 μM each forward pri-
mer (5´-TCTGGGAAGGGACAGAAGATGAC-3´) and re-
verse primer (5´-TTGCCGTCCCAAGCAATGGATGA-3´), 
1.5 mM MgCl2, 0.8 mM dNTPs, 1.25 unit Taq DNA 
polymerase (Thermo Scientific). The PCR conditions 
were as follows: initial denaturation step of 3 min 
at 95 °C, 35 cycles of 30 s at 95 °C, 30 s of annealing 
at 57 °C, and 30 s of extension at 72 °C. The amplified 
199-bp fragments were digested with BstUI (Thermo 
Scientific) by the manufacturers’ protocols. The di-
gested PCR products were resolved on 3% agarose 
gel containing ethidium bromide and visualized under 
UV light. The presence of the TP53 72G allele re-
sulted in the digestion of the amplicon to 113 bp and 
86 bp products, the presence of 72C allele displayed 
as non-digested 199-bp product (Fig. 2).
Fig. 1. Sequencing data of observed CLL patients' samples for 
TP53 exon 4 analysis (region of TP53 codon 72 SNP location): 
GG (Arg/Arg), CG (Arg/Pro), CC (Pro/Pro) genotypes
1 2 3 4 5 6 7 8 9 10 11 50 bp
— 200 bp
— 100 bp
— 50 bp
Fig. 2. Results of TP53 codon 72 polymorphism detection 
by polymerase chain reaction and digestion with BstUI in ob-
served CLL patients: Line 1, 3, 4, 6, 7 and 8 — Arg/Arg genotype 
(86 bp and 113 bp bands); line 2, 9, 10 and 11 — Arg/Pro genotype 
(86 bp, 113 bp and 199 bp bands); line 5 — Pro/Pro genotype 
(199 bp band); 50 bp DNA size markers
Statistics were performed using the SPSS 
16.0 software package (SPSS, Chicago, IL). 
TP53 rs1042522 polymorphism was tested for devia-
tion from the Hardy — Weinberg equilibrium by com-
paring the observed and expected genotype frequen-
cies using the χ2 test with one degree of freedom. Data 
shown are the means plus or minus standard devia-
tions, and medians. The χ2 test for categorical variables 
was used to compare characteristics between diffe-
rent subgroups of patients. The relative significance 
of different factors on TP53 mutation occurrence was 
evaluated by univariate and multivariate analysis. All 
tests were two-sided and considered to be statistically 
significant with a p-value of < 0.05.
RESULTS AND DISCUSSION
Analysis of the TP53 codon 72 polymorphism in 261 CLL 
patients resulted in frequencies of 0.68 and 0.32 for 
the G and C allele, respectively (Arg/Arg — 124 cases, 
47.5%; Arg/Pro — 109 cases, 41.8%; Pro/Pro — 28 cases, 
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10.7%). Genotype frequencies did not differ sig-
nificantly from those predicted by Hardy — Weinberg 
equilibrium (χ2 = 1.29; p = 0.273). These results are 
comparable with data from CLL group presented 
by Sturm et al. [26] (Arg/Arg — 57.3%; Arg/Pro — 
36.1%; Pro/Pro — 6.6%).
TP53 mutations were found in 21 of 261 patients 
(8%) in this study. Most of mutations were detected 
in the DNA-binding domain (exons 5–8), namely, 
in exon 5 (4 patients), exon 6 (5 patients), exon 7 (4 pa-
tients), and exon 8 (3 patients). In three patients TP53 mu-
tations were detected in exon 9 (C-terminal region) 
and in two patients — in exon 4 (proline rich region). 
Of the 28 cases homozygous for the 72Pro allele, 
7 cases (25%) carried mutation in the TP53 gene. 
In contrast, of the 124 cases which were homozy-
gous for the 72Arg allele, 6 cases only (4.8%) had 
the TP53 mutation (Table 2). Thus, TP53 mutations 
were significantly more often found in CLL patients 
carriers of Pro/Pro genotype (p = 0.002).
Table 2. TP53 mutations in relation to the TP53 codon 72 genotypes and 
previous therapy
CLL patients The frequency of TP53 mutations, cases (%) p valueArg/Arg Arg/Pro Pro/Pro
All patients, n=261 6 of 124 (4.8) 8 of 109 (7.3) 7 of 28 (25.0) 0.002
Untreated, n=172 5 of 85 (5.9) 2 of 70 (2.9) 0 of 17 (0.0) 0.427
Treated, n=89 1 of 39 (2.6) 6 of 39 (15.4) 7 of 11 (63.6) 0.0001
Previously treated patients showed a higher 
frequency of TP53 mutations in comparison with 
untreated patients (p = 0.001). Time to treatment 
(p = 0.446), duration of therapy (p = 0.997) did not 
differ significantly in carriers of different TP53 co-
don 72 genotypes. The incidence of TP53 mutations 
among previously treated patients was also higher 
in carriers of the Pro/Pro genotype comparing to carri-
ers of the other genotypes (p = 0.0001), and in carriers 
of the Pro allele comparing to carriers of the Arg/Arg 
genotype (13 of 50 patients, 26.0% and 1 of 39 pa-
tients, 2.6%, correspondingly; p = 0.003). At the same 
time, among untreated patients the distribution 
of TP53 mutations did not differ in carriers of different 
genotypes (p = 0.427) and in carriers of the Pro allele 
in comparison with carriers of the Arg/Arg genotype 
(2 of 87 patients, 2.3% and 5 of 85 patients, 5.9%, 
correspondingly; p = 0.234). The risk of TP53 mu-
tations occurrence among pretreated patients was 
increased in carriers of the Pro allele (Odds ratio, 
OR = 1.317; 95% confidence interval, CI 1.109–1.564) 
and in carriers of the Pro/Pro genotype (OR = 2.503; 
95% CI 1.142–5.487).
To estimate the impact of some clinical and biologi-
cal factors on the incidence of TP53 mutations we used 
univariate Cox regression analysis. Clinical data at diag-
nosis were available for the most of CLL cases. Several 
factors were included: age of patients (cut-off point 
at 65 years), gender, Binet stage at diagnosis, initial 
WBC count (cut-off point at 100•109/L), IGHV mutati-
onal status, previous treatment, TP53 codon 72 geno-
type. As shown in Table 3, the 72Pro/Pro genotype, 
previous treatment and Binet stage B only correlated 
significantly with the occurrence of TP53 mutations. 
Multivariate Cox regression analysis confirmed an in-
dependent significance of abovementioned factors for 
TP53 mutations occurrence.
Table 3. Significance of some clinical and biological factors for occurrence 
of TP53 mutations under univariate and multivariate Cox regression analysis
Factors N
Univariate 
analysis
Multivariate 
analysis
TP53 muta-
tions, n (%) p value p value
Age (years)
> 65 62 9.7 (6) 0.629 0.344< 65 194 7.7 (15)
Sex
Male 195 9.6 (19) 0.102 0.741Female 63 3.2 (2)
Binet stage at diagnosis
A 133 4.5 (6)
0.076 −B 97 13.4 (13)
C 31 6.5 (2)
Binet stage at diagnosis
B 97 13.4 (13) 0.011 0.023A + C 164 4.9 (8)
Initial WBC counts, · 109/L
> 100 30 10.0 (3) 0.703 0.509< 100 226 8.0 (18)
IGHV genes
M 92 5.4 (5) 0.346 0.396UM 161 8.7 (14)
TP53 codon 72 genotypes
Pro/Pro 28 25.0 (7) 0.001 0.001Arg/Arg+Arg/Pro 231 6.1 (14)
Treatment
Untreated 172 4.1 (7) 0.001 0.001Treated 89 15.7 (14)
Thus, our data are in agreement with results 
of Grossmann et al. [15] and Dong et al. [16], who 
have found an increased incidence of TP53 mutations 
in CLL patients, carriers of the 72Pro/Pro genotype. 
However, we found that the frequency of TP53 muta-
tions in 72Pro homozygotes was increased only after 
previous treatment.
The TP53 codon 72 alleles encode an arginine 
amino acid with a positive-charged basic side chain 
and a proline residue with a nonpolar-aliphatic side 
chain, which have different biochemical properties and 
different binding to components of the transcriptional 
machinery [27]. On the other hand, it is known that 
purine analogues and alkylating agents induce a TP53-
dependent gene expression response [28, 29], and 
the occurrence of TP53 gene alterations in CLL patients 
is associated with previous chemotherapy by these 
drugs [30]. It is possible, that some conformational fea-
tures of TP53 protein and TP53-containing complexes 
in carriers of the Pro/Pro genotype contribu te to the de-
velopment of TP53 mutations under drug-induced high 
expression of this gene. Another possible explanation 
of our findings may by related to different functional 
properties of TP53 polymorphic variants. The 72Arg 
is more effective at inducing apoptosis than the 72Pro 
variant, while the Pro/Pro genotype is associated with 
an increased expression of cell cycle arrest genes [14]. 
Preferential cell cycle arrest and slowing apoptosis may 
contribute to an inadequate repair of DNA damages 
under action of genotoxic stimulus and accumulation 
of cells with TP53 mutations.
In summary, our preliminary data suggested that CLL 
patients with the Pro/Pro genotype are a risk group for de-
velopment of TP53 mutations under modern treatment.
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